Specifically, QUE’s drug combination inhibited CD4+T cells differentiate to Th2, tumor-associated neutrophils differentiate to N2 type, and tumor-associated macrophages differentiate to M2 type (144). This evidence concerns the gene CD4 and neoplasm.